Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous

被引：9
|
作者：
Lawitz, EJ
Bala, NS
Becker, S
Brown, G
Davis, M
Dhar, R
Ganeshappa, KP
Gordon, S
Holtzmuller, K
Jeffries, M
Li, JJ
Monsour, H
Nader, P
Rosenfield, T
Tolman, K
Kadakia, S
机构：
来源：
GASTROENTEROLOGY | 2003年 / 124卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(03)83957-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A783 / A784
页数：2
相关论文
共 50 条
  • [1] Pegylated interferon alfa 2b (PEG-IFN) and ribavirin for hepatitis C patients who were nonresponders to previous therapy
    Lawitz, EJ
    Cantu, NS
    Becker, S
    Dhar, R
    Li, J
    Bala, NS
    Gordon, S
    Davis, M
    Nader, P
    Holtzmuller, K
    Rosenfield, T
    Monsour, H
    GASTROENTEROLOGY, 2002, 122 (04) : A626 - A626
  • [2] Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin
    Carroll B. Leevy
    Digestive Diseases and Sciences, 2008, 53 (7) : 2009 - 2009
  • [3] Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin
    Carroll B. Leevy
    Digestive Diseases and Sciences, 2008, 53 : 1961 - 1966
  • [4] Consensus interferon and ribavirin in patients with chronic hepatitis c who were nonresponders to pegylated interferon alfa-2b and ribavirin
    Leevy, Carroll B.
    DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (07) : 1961 - 1966
  • [5] Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to prior therapy with either interferon alfa and ribavirin or pegylated interferon and ribavirin
    Chen, K
    Seraphin, P
    Murphy, L
    Shah, N
    HEPATOLOGY, 2005, 42 (04) : 670A - 670A
  • [6] Pegylated interferon alfa 2b (PEG-IFN) and ribavirin for hepatitis C patients who were previous nonresponders to standard combination therapy: 24 week viral clearance.
    Lawitz, EJ
    Jeffries, MA
    Cantu, NS
    Kadakia, SC
    HEPATOLOGY, 2001, 34 (04) : 338A - 338A
  • [7] Triple therapy compared to standard Pegylated Interferon Alfa 2b plus weight based Ribavirin for previous nonresponders and relapsers with chronic hepatitis C.
    Lawitz, EJ
    Cantu, NS
    Davis, M
    Afdhal, N
    Curry, M
    Mailliard, M
    Adams, F
    Tsai, N
    Gasic, A
    Kothari, T
    Ganeshappa, KP
    Cox, J
    Silverman, B
    Kadakia, SC
    HEPATOLOGY, 2003, 38 (04) : 742A - 742A
  • [8] Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment
    Franchini, M
    Tagliaferri, A
    Rossetti, G
    Capra, F
    Veneri, D
    De Maria, E
    Pattacini, C
    Aprili, G
    Gandini, G
    HAEMOPHILIA, 2002, 8 (06) : 794 - 797
  • [9] Pegylated interferon α-2b, ribavirin and amantadine for chronic hepatitis C
    Younossi, ZM
    McCullough, A
    Barnes, D
    Post, A
    Ong, J
    O'Shea, R
    Martin, LM
    Bringman, D
    Farmer, D
    Levinthal, G
    Mullen, KD
    Carey, WD
    Tavill, AS
    Ferguson, R
    Gramlich, T
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (05) : 970 - 975
  • [10] Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C
    Zobair M. Younossi
    Arthur C. McCullough
    David S. Barnes
    Anthony Post
    Janus P. Ong
    Robert O’shea
    Lisa M. Martin
    Diane Bringman
    Denise Farmer
    Gavin Levinthal
    Kevin D. Mullen
    William D. Carey
    Anthony S. Tavill
    Roy Ferguson
    Terry Gramlich
    Digestive Diseases and Sciences, 2005, 50 : 970 - 975
12345